Searched over 200M research papers
10 papers analyzed
These studies suggest non-selective beta-blockers are effective in treating cirrhosis-related complications, reducing mortality, and potentially lowering hepatocellular carcinoma risk, though their safety in advanced liver disease remains uncertain.
20 papers analyzed
Non-selective beta blockers (NSBBs) are a class of medications that inhibit the action of endogenous catecholamines on both beta-1 and beta-2 adrenergic receptors. These drugs are widely used in various clinical settings, including the management of hypertension, cirrhosis, and certain types of cancer . This article synthesizes recent research on the efficacy, safety, and clinical outcomes associated with NSBBs.
NSBBs are a cornerstone in the management of portal hypertension in cirrhotic patients, particularly for preventing variceal bleeding. Studies have shown that NSBBs like propranolol and nadolol are effective in reducing the risk of initial and recurrent variceal bleeding . However, the efficacy of NSBBs in reducing mortality remains debated. A meta-analysis comparing banding ligation and NSBBs for primary prevention of variceal bleeding found no significant difference in mortality rates between the two interventions, although banding ligation was more effective in reducing bleeding episodes.
Recent meta-analyses suggest that NSBBs may also play a role in reducing the incidence of hepatocellular carcinoma (HCC) in cirrhotic patients. Specifically, nadolol and carvedilol have been associated with a significant reduction in HCC risk, while propranolol and timolol did not show a similar effect . This suggests that the benefits of NSBBs may extend beyond hemodynamic improvements to include anti-cancer properties.
Despite their benefits, the use of NSBBs in patients with advanced liver disease, such as those with refractory ascites or spontaneous bacterial peritonitis, has raised safety concerns. Studies indicate that NSBBs may increase the risk of renal insufficiency and mortality in these patients, leading to the "window hypothesis," which posits that NSBBs are beneficial only up to a certain stage of liver disease. Therefore, careful consideration is required before continuing NSBB therapy in advanced cirrhosis.
A prospective observational study found that ongoing use of NSBBs in patients with ACLF was associated with reduced 28-day mortality and lower systemic inflammation, as evidenced by reduced white cell counts. This suggests that NSBBs may have immunomodulatory effects that contribute to improved short-term survival in ACLF patients.
NSBBs have been used for blood pressure control since the mid-20th century. They are particularly effective in reducing cardiovascular events in hypertensive patients. However, their use has declined in favor of newer agents with fewer side effects. Despite this, NSBBs remain a valuable option for patients with specific indications, such as those with concurrent cirrhosis or certain types of cancer.
The role of NSBBs in cancer recurrence and survival has been explored in various studies. While NSBBs did not show a significant effect on cancer recurrence overall, they were associated with improved disease-free survival (DFS) and overall survival (OS) in specific cancers like ovarian and melanoma. Conversely, NSBBs were linked to reduced OS in lung cancer, highlighting the variability in their effects across different cancer types.
Non-selective beta blockers are versatile medications with applications ranging from the management of portal hypertension in cirrhosis to potential roles in cancer therapy. While they offer significant benefits, particularly in reducing variceal bleeding and possibly HCC incidence, their use in advanced liver disease requires careful consideration due to potential safety concerns. Further research is needed to fully elucidate the benefits and limitations of NSBBs in various clinical settings.
Most relevant research papers on this topic